The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study

The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human study

Abstract Background 223Ra is currently used for treatment of metastatic castration resistant prostate cancer patients (mCRPC) bone metastases with fixed standard activity. Individualized treatments, based on adsorbed dose (AD) in target and non-target tissue, are absolutely needed to optimize effica...

Full description

Bibliographic Details
Main Authors: Rosa Sciuto, Sandra Rea, Sara Ungania, Antonella Testa, Valentina Dini, Maria Antonella Tabocchini, Clarice Patrono, Antonella Soriani, Valentina Palma, Raffaella Marconi, Lidia Strigari
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Dosimetry
Biological effects
223Ra
Online Access:https://doi.org/10.1186/s13046-021-02056-9

Internet

https://doi.org/10.1186/s13046-021-02056-9

Similar Items